These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1567 related articles for article (PubMed ID: 32903444)
1. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
4. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
6. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
7. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer. Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G Front Immunol; 2023; 14():1298524. PubMed ID: 38187388 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695 [TBL] [Abstract][Full Text] [Related]
10. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271 [TBL] [Abstract][Full Text] [Related]
11. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272 [TBL] [Abstract][Full Text] [Related]
12. Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. Mou W; Zhu L; Yang T; Lin A; Lyu Q; Guo L; Liu Z; Cheng Q; Zhang J; Luo P Cancer Cell Int; 2022 Jul; 22(1):229. PubMed ID: 35836254 [TBL] [Abstract][Full Text] [Related]
13. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779 [TBL] [Abstract][Full Text] [Related]
14. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. Almquist DR; Ahn DH; Bekaii-Saab TS BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441 [TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms. Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939 [TBL] [Abstract][Full Text] [Related]
16. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787 [TBL] [Abstract][Full Text] [Related]
17. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies. Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588 [TBL] [Abstract][Full Text] [Related]
18. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]